RxDoctor Payments Data

Kevin Steinberg, MD

Interventional Cardiology · Philadelphia, PANPI 1376698852

Payments from drug & device makers

$2,425in general payments, 2019–2025

Across 25 payments — averaging $97.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BD$2K
  • Boston Scientific$447
  • Heartflow, Inc.$103
  • Amgen$65
  • AstraZeneca$40
  • Abbott$36
  • plus $230 from 10 others

What the payments were for

  • Speaking & faculty fees$1,50562%
  • Food & beverage$92038%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,425 in reported general payments places this provider in the 15th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$126,536
Medicare patients
765
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban263$261,125
Repatha SureclickEvolocumab206$134,056
XareltoRivaroxaban89$90,414
EntrestoSacubitril/Valsartan66$68,594
JardianceEmpagliflozin45$67,252
Praluent PenAlirocumab100$55,028
MounjaroTirzepatide46$46,561
VascepaIcosapent Ethyl69$34,429
OzempicSemaglutide32$29,269
WegovySemaglutide18$23,791
BrilintaTicagrelor13$13,032
TrulicityDulaglutide13$12,758
Icosapent Ethyl41$12,166
Ezetimibe417$11,647
Atorvastatin Calcium655$10,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$261,125263 claims
NovartisEntresto$15$68,59466 claims
Novo NordiskOzempic, Wegovy$24$53,05950 claims
AstraZenecaBrilinta$40$13,03213 claims
Esperion Therapeutics, Inc.Nexletol$24$5,02113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →